Shibata T, Yamamoto F, Kosakai Y, Kawazoe K, Komai H, Ichikawa H, Ohashi T, Shimada Y, Nakajima N, Kawashima Y
Department of Cardiovascular Surgery, National Cardiovascular Center, Osaka, Japan.
Nihon Kyobu Geka Gakkai Zasshi. 1993 Mar;41(3):427-32.
We have applied recombinant human superoxide dismutase (RH-SOD) to prevent ischemia reperfusion injury in the patients who received open heart surgery. Twenty-four patients were divided into 2 groups; group A had no treatment as control and group B received bolus injection of RH-SOD (35,000 IU/kg) into cardiopulmonary bypass 5 minutes before reperfusion. Arterial and coronary sinus blood was collected to measure chemiluminescence (ChL) value, SOD activity, lactate and pyruvate level, and several parameters of myocardial oxygen metabolism after reperfusion. Arterio-venous difference of ChL value showed the tendency of less ChL generation of the heart in group B compared with those in group A. But no other parameters showed significant difference between the two groups. Our data suggested that this way of the administration of RH-SOD failed to improve the myocardial protection during open heart surgery. Further investigation, such as dose response study, might be required to determine whether RH-SOD possess beneficial effects or not in the clinical setting.
我们已将重组人超氧化物歧化酶（RH-SOD）应用于接受心脏直视手术患者的缺血再灌注损伤预防。24例患者分为2组；A组未接受治疗作为对照，B组在再灌注前5分钟经体外循环给予大剂量注射RH-SOD（35,000 IU/kg）。收集动脉血和冠状窦血以测量化学发光（ChL）值、SOD活性、乳酸和丙酮酸水平以及再灌注后心肌氧代谢的几个参数。ChL值的动静脉差值显示，与A组相比，B组心脏产生的ChL有减少的趋势。但两组之间的其他参数均无显著差异。我们的数据表明，这种给予RH-SOD的方式未能改善心脏直视手术期间的心肌保护。可能需要进一步研究，如剂量反应研究，以确定RH-SOD在临床环境中是否具有有益作用。
